These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

995 related articles for article (PubMed ID: 25545165)

  • 41. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.
    Schneider V; Zhang L; Rojewski M; Fekete N; Schrezenmeier H; Erle A; Bullinger L; Hofmann S; Götz M; Döhner K; Ihme S; Döhner H; Buske C; Feuring-Buske M; Greiner J
    Int J Cancer; 2015 Nov; 137(9):2083-92. PubMed ID: 25912930
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identifying leukemia stem cells--is it feasible and does it matter?
    Lutz C; Hoang VT; Buss E; Ho AD
    Cancer Lett; 2013 Sep; 338(1):10-4. PubMed ID: 22820159
    [TBL] [Abstract][Full Text] [Related]  

  • 43. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
    Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ENPP4 and HOXA3 as potential leukaemia stem cell markers in acute myeloid leukaemia.
    Mohd Amin A; Panneerselvan N; Md Noor S; Mohtaruddin N; Sathar J; Norbaya WS; Osman R; Kee LH; Mohd Yaakub WH; Cheong SK; Abdullah M
    Malays J Pathol; 2023 Apr; 45(1):65-76. PubMed ID: 37119247
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia.
    Nakamura S; Hirano I; Okinaka K; Takemura T; Yokota D; Ono T; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
    Carcinogenesis; 2010 Nov; 31(11):2012-21. PubMed ID: 20823107
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
    Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
    Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML.
    Grenier JMP; Testut C; Bal M; Bardin F; De Grandis M; Gelsi-Boyer V; Vernerey J; Delahaye M; Granjeaud S; Zemmour C; Spinella JF; Chavakis T; Mancini SJC; Boher JM; Hébert J; Sauvageau G; Vey N; Schwaller J; Hospital MA; Fauriat C; Aurrand-Lions M
    Blood Adv; 2024 Sep; 8(17):4662-4678. PubMed ID: 38954834
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.
    Jajosky AN; Coad JE; Vos JA; Martin KH; Senft JR; Wenger SL; Gibson LF
    Stem Cells Transl Med; 2014 Jul; 3(7):836-48. PubMed ID: 24855276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High ALDHdim-expressing CD34+CD38- cells in leukapheresed peripheral blood is a reliable guide for a successful leukemic xenograft model of acute myeloid leukemia.
    Lee JY; Park S; Han AR; Lim J; Min WS; Kim HJ
    Oncol Rep; 2014 Oct; 32(4):1638-46. PubMed ID: 25069538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
    Terwijn M; Zeijlemaker W; Kelder A; Rutten AP; Snel AN; Scholten WJ; Pabst T; Verhoef G; Löwenberg B; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    PLoS One; 2014; 9(9):e107587. PubMed ID: 25244440
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.
    Majeti R
    Best Pract Res Clin Haematol; 2014; 27(3-4):229-34. PubMed ID: 25455271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow.
    Paubelle E; Zylbersztejn F; Maciel TT; Carvalho C; Mupo A; Cheok M; Lieben L; Sujobert P; Decroocq J; Yokoyama A; Asnafi V; Macintyre E; Tamburini J; Bardet V; Castaigne S; Preudhomme C; Dombret H; Carmeliet G; Bouscary D; Ginzburg YZ; de Thé H; Benhamou M; Monteiro RC; Vassiliou GS; Hermine O; Moura IC
    Cell Rep; 2020 Jan; 30(3):739-754.e4. PubMed ID: 31968250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
    Qi J; Singh S; Hua WK; Cai Q; Chao SW; Li L; Liu H; Ho Y; McDonald T; Lin A; Marcucci G; Bhatia R; Huang WJ; Chang CI; Kuo YH
    Cell Stem Cell; 2015 Nov; 17(5):597-610. PubMed ID: 26387755
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long noncoding RNA HOTAIR promotes the self-renewal of leukemia stem cells through epigenetic silencing of p15.
    Gao S; Zhou B; Li H; Huang X; Wu Y; Xing C; Yu X; Ji Y
    Exp Hematol; 2018 Nov; 67():32-40.e3. PubMed ID: 30172749
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
    Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
    Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Leukemia stem cells.
    Buss EC; Ho AD
    Int J Cancer; 2011 Nov; 129(10):2328-36. PubMed ID: 21796620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
    Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
    Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.